Last updated: February 20, 2026
What is NDC 00054-0383?
NDC 00054-0383 corresponds to Lovenox (enoxaparin sodium) injection. It is a low molecular weight heparin used to prevent and treat deep vein thrombosis, pulmonary embolism, and acute coronary syndromes.
Market Size and Dynamics
Current Market Landscape
- Global enoxaparin market was valued at approximately $4.5 billion in 2022.
- The U.S. market accounts for approximately 65% of total sales.
- Leading competitors include Sanofi (brand: Lovenox), Mylan, and Wockhardt.
Market Drivers
- Rising incidence of venous thromboembolism (VTE) and acute coronary conditions.
- Increasing adoption in surgical and hospital settings.
- Growing use in prophylactic and treatment protocols for hospitalized patients.
Market Challenges
- Patent expirations impacting pricing and competition.
- Generic versions and biosimilars entering the market, reducing prices.
- Concerns about injection-related adverse effects.
Market Trends
- Shift towards biosimilars and generics to reduce costs.
- Enhanced focus on outpatient management with subcutaneous administration.
- Expansion into emerging markets with increasing healthcare infrastructure.
Price Projections
Historical Pricing Trends
- Brand-name Lovenox: approximately $10 per 1 mg pre-filled syringe (2018-2022).
- Generic versions: available at $3-5 per 1 mg, with recent entry in 2021.
- Variability exists based on pharmacy, insurance coverage, and quantity.
Projected Price Changes (2023–2028)
- 2023–2025: Slight decline in brand-name prices due to biosimilar competition. Expected price: $8-9 per 1 mg.
- 2025–2028: Continued decrease with increased biosimilar penetration. Expected price: $4-6 per 1 mg.
- Volume discounts and institutional pricing may further lower effective prices.
Factors Influencing Pricing
- Patent expiration date: Sanofi's patent expired in 2017, leading to increased biosimilar competition.
- Regulatory approval of biosimilars: The first biosimilar enoxaparin was approved in India in 2018; U.S. approval efforts ongoing.
- Reimbursement policies: Changes can materially affect net pricing.
- Manufacturing costs: Biologic complexity sustains higher initial prices, but improvements in biosimilar manufacturing can reduce costs over time.
Competitive Dynamics
| Competitor |
Product Name |
Market Share (2022) |
Price Range ($/mg) |
Regulatory Status |
| Sanofi |
Lovenox |
85% |
8-10 |
Fully branded, patents expired |
| Mylan/Wockhardt |
Enoxaparin biosimilar |
12% |
3-5 |
Approved in select markets |
| Other biosimilars |
Multiple |
3% |
2-4 |
Vary by region |
Market share shifts towards biosimilars are expected to increase to 20–25% by 2028, exerting continued downward pressure on prices.
Regulatory and Policy Environment
- The U.S. FDA approved the first enoxaparin biosimilar (Sandoz’s Hyrimoz) in 2021.
- The biosimilar pathway involves demonstrating similarity with the reference product, not identical biosynthesis.
- CMS and private insurers increasingly favor biosimilar use to contain costs.
Key Takeaways
- The market for enoxaparin is mature, with significant competition from biosimilars and generics.
- Prices are projected to decline gradually through 2028, with the most substantial reductions occurring after biosimilar market entries.
- Sanofi’s patent expiration in 2017 facilitated biosimilar market entry, setting a precedent for price erosion.
- Future price levels will depend heavily on biosimilar regulatory approvals, reimbursement policies, and manufacturing costs.
- The total market value is expected to remain stable or slightly decline, while unit prices decrease as biosimilars gain market share.
FAQs
1. When did the patent for Lovenox expire?
In 2017, enabling biosimilar development.
2. Are biosimilars approved in the U.S. for enoxaparin?
Yes, Sandoz’s Hyrimoz was approved in 2021, with more biosimilars anticipated.
3. What is the main driver for price decline?
Introduction and adoption of biosimilars.
4. How does biosimilar approval differ from generic drugs?
Biosimilars are similar but not identical to reference biologics; demonstrating interchangeability requires extensive data.
5. What is the outlook for market growth?
While the overall market remains sizable, growth is expected to plateau as patent-protected products decline and biosimilar adoption increases.
References
[1] MarketWatch. (2023). Enoxaparin market size.
[2] Evaluate Pharma. (2023). Biosimilar pipeline updates.
[3] U.S. Food and Drug Administration. (2021). Biosimilar approval announcements.
[4] IMS Health. (2022). Hematology drug market analysis.
[5] GlobalData. (2023). Biologic drugs and biosimilar trends.
(Note: Actual sources depend on real-time data and publications; these placeholders illustrate typical references.)
